Global Gliflozin market, By Type (Invokana, Farxiga, Jardiance, Steglatro), Side Effects (Urinary Tract Infections, Yeast Infections, Diabetic Ketoacidosis, Hypoglycemia, Hypotension), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Gliflozin Market
Gliflozin market is expected to gain market growth at a potential rate of 7.80% in the forecast period of 2021 to 2028. Rise in the number of these diseases is the vital factor escalating the market growth.
SGLT2 inhibitors are also known as gliflozins, which are a class of medications that alter essential physiology of the nephron; unlike SGLT1 inhibitors which modulate sodium/glucose channels in the intestinal mucosa.
Increase in incidence of chronic diseases o will uplift the market growth, also rise in the prevalence of the disease, rise in the healthcare affordability in the US and rise in the knowledge and awareness amongst the people are some of the crucial factors among others driving the gliflozin market growth. Moreover, rise in the personalized medicines for the treatment, rise in the research and development activities in the market and rise in the collaborations for product development will further create new opportunities for the gliflozin market in the forecast period of 2021-2028.
However, rise in the lack of patient awareness, side effects associated with drugs, and poor reimbursement in the market are the major factors among others acting as restraints, and will further challenge the gliflozin market in the forecast period mentioned above.
Gliflozin market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the gliflozin market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Gliflozin Market Scope and Market Size
Gliflozin market is segmented on the basis of type and side effects. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, gliflozin market is segmented into invokana, farxiga, jardiance and steglatro.
- Gliflozin market is also segmented on the basis of side effects into urinary tract infections, yeast infections, diabetic ketoacidosis, hypoglycemia and hypotension.
Gliflozin Market Country Level Analysis
Gliflozin market is analysed and market size information is provided by country, type and side effects as referenced above.
The countries covered in the gliflozin market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the gliflozin market due to rise in the prevalence of the disease, rise in the healthcare affordability in the U.S. and rise in the knowledge and awareness amongst the people in this region.
The country section of the gliflozin market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Gliflozin market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Gliflozin Market Share Analysis
Gliflozin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to gliflozin market.
The major players covered in the gliflozin market report are Pfizer Inc., AstraZeneca, Eli Lilly and Company, Abiogen Pharma S.p.A., Merck Sharp & Dohme Corp., Novartis AG, GlaxoSmithKline plc., Zimmer Biomet, Johnson & Johnson Private Limited, Ampio Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Abbott, AbbVie Inc., Astellas Pharma Inc., BioDelivery Sciences International, Inc.., Crystal Genomics, Daiichi-Sankyo Company Limited, and Endo Pharmaceuticals Inc among other domestic and global players. Gliflozin market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-